lobbying_activities: 2023789

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2023789	70f65bde-06ef-4f03-acc4-ebeef51b20b8	Q3	ACADEMY OF MANAGED CARE PHARMACY	48793	ACADEMY OF MANAGED CARE PHARMACY	2017	third_quarter	PHA	Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace.	Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		80000	0	0	2017-10-13T15:08:28.210000-04:00